Novo to Sue Aventis Over Long-acting Insulin – Claims Patent Infringement


By: dhtest

On April 27, three days after glargine (Lantus) was approved by the U.S. Food and Drug Administration, Novo Nordisk filed a lawsuit with the Court of Dusseldorf in Germany against Aventis for patent infringement.

Novo claims that the production and sale of the 24-hour basal insulin infringes two German patents held by Novo Nordisk.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.